Palliative Hepatectomy for Advanced Hepatocellular Carcinoma with Multiple Metastases: A Case Report

  • Lee, Jae-Myeong (Department of Surgery, Ajou University School of Medicine, Division of Hepato-Biliary & Pancreas Surgery) ;
  • Park, Kwang-Min (Department of Surgery, University of Ulsan College of Medicine, Asan Medical Center) ;
  • Choi, Julian (Department of Surgery, University of Ulsan College of Medicine, Asan Medical Center) ;
  • Chon, Sang-Hoon (Department of Surgery, University of Ulsan College of Medicine, Asan Medical Center) ;
  • Hwang, Dae-Wook (Department of Surgery, University of Ulsan College of Medicine, Asan Medical Center) ;
  • Lee, Young-Joo (Department of Surgery, University of Ulsan College of Medicine, Asan Medical Center)
  • Published : 2009.12.31

Abstract

Non-surgical treatment is usually performed for the cases of hepatocellular carcinoma (HCC) that are not suitable for curative treatment, such as those cases with a large tumor size with an insufficient hepatic remnant after resection, those cases with extensive and multifocal bilobar tumors or those cases with extrahepatic metastases of the disease. However, in this case report we present a case of palliative hepatectomy for treating advanced HCC with multiple metastases and the patient has had an excellent 1-year follow-up outcome. A 71-year-old man was referred to our hospital and the imaging studies showed a 10 cm mass in the right liver, with multiple variable sized masses in both lungs and a 1 cm nodule in the left adrenal gland. A lung biopsy revealed HCC; therefore, the working diagnosis was HCC with multiple lung metastases and a left adrenal gland adenoma or metastasis. We expected the cause of death would be deterioration of the hepatic function as the liver mass increased in size. Therefore, we performed a palliative right trisectionectomy for the primary liver mass. After recovery from the hepatectomy, the patient was managed with sorafenib. During the 1-year follow-up period after palliative hepatectomy, the patient is still alive with a good general performance status and no evidence of intrahepatic recurrence, even though there has been an aggravation of the lung metastases in size and number, and a slight increase in the size of the left adrenal gland. We suggest that in highly selected patients with advanced HCC and multiple extrahepatic metastases, and especially in the cases involving a large HCC with mild liver cirrhosis and a good general performance status, an aggressive treatment strategy with palliative hepatectomy can be an optional treatment modality to improve the overall survival.

Keywords

References

  1. Lau WY, Lai EC. Hepatocellular carcinoma: current management and recent advances. Hepatobiliary Pancreat Dis Int 2008;7:237-257.
  2. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003;362:1907-1917. https://doi.org/10.1016/S0140-6736(03)14964-1
  3. Borie F, Bouvier AM, Herrero A, et al. Treatment and prognosis of hepatocellular carcinoma: a population based study in France. J Surg Oncol 2008;98:505-509. https://doi.org/10.1002/jso.21159
  4. Lai EC, Lau WY. The continuing challenge of hepatic cancer in Asia. Surgeon 2005;3:210-215. https://doi.org/10.1016/S1479-666X(05)80043-5
  5. Lau WY, Yu SC, Lai EC, Leung TW. Transarterial chemoembolization for hepatocellular carcinoma. J Am Coll Surg 2006; 202:155-168. https://doi.org/10.1016/j.jamcollsurg.2005.06.263
  6. McCarter MD, Fong Y. Role for surgical cytoreduction in multimodality treatments for cancer. Ann Surg Oncol 2001; 8:38-43. https://doi.org/10.1007/s10434-001-0038-0
  7. Lau WY, Leung TW, Leung KL, et al. Cytoreductive surgery for hepatocellular carcinoma. Surg Oncol 1994;3:161-166. https://doi.org/10.1016/0960-7404(94)90045-0
  8. Nagashima J, Okuda K, Tanaka M, Sata M, Aoyagi S. Prognostic benefit in cytoreductive surgery for curatively unresectable hepatocellular carcinoma - comparison to transcatheter arterial chemoembolization. Int J Oncol 1999;15: 1117-1123.
  9. Inman JL, Kute T, White W, Pettenati M, Levine EA. Absence of HER2 overexpression in metastatic malignant melanoma. J Surg Oncol 2003;84:82-88. https://doi.org/10.1002/jso.10297
  10. Lai EC, Tang CN, Ha JP, Tsui DK, Li MK. Cytoreductive surgery in multidisciplinary treatment of advanced hepatocellular carcinoma. ANZ J Surg 2008;78:504-507. https://doi.org/10.1111/j.1445-2197.2008.04544.x
  11. Lau WY, Lai EC. Salvage surgery following downstaging of unresectable hepatocellular carcinoma--a strategy to increase resectability. Ann Surg Oncol 2007;14:3301-3309. https://doi.org/10.1245/s10434-007-9549-7
  12. Bruix J, Sherman M; Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology 2005; 42:1208-1236. https://doi.org/10.1002/hep.20933
  13. Pandey D, Tan KC. Surgical resection of adrenal metastasis from primary liver tumors: a report of two cases. Hepatobiliary Pancreat Dis Int 2008;7:440-442.
  14. Imamura I. Prognostic efficacy of treatment for extrahepatic metastasis after surgical treatment of hepatocellular carcinoma. Kurume Med J 2003;50:41-48. https://doi.org/10.2739/kurumemedj.50.41
  15. Aramaki M, Kawano K, Kai T, et al. Treatment for extrahepatic metastasis of hepatocellular carcinoma following successful hepatic resection. Hepatogastroenterology 1999;46: 2931-2934.
  16. Keating GM, Santoro A. Sorafenib: a review of its use in advanced hepatocellular carcinoma. Drugs 2009;69:223-240. https://doi.org/10.2165/00003495-200969020-00006
  17. Poon RT, Fan ST, O'Suilleabhain CB, Wong J. Aggressive management of patients with extrahepatic and intrahepatic recurrences of hepatocellular carcinoma by combined resection and locoregional therapy. J Am Coll Surg 2002;195: 311-318. https://doi.org/10.1016/S1072-7515(02)01226-7